Previous 10 | Next 10 |
home / stock / otlkw / otlkw news
Drs. Mark Humayun and Firas Rahhal, leading retinal specialists and Advisors to Outlook Therapeutics, stress clinical value of ONS-5010, if approved, over existing treatment options Registration clinical program and pre-commercialization planning for ONS-5010 remains ongoin...
Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on target to report in calendar Q3 2021 Recently reported topline data from the NORSE THREE open-label safety study reinforce positive safety profile of ONS-5010 seen in the earlier clinical experience tri...
ISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, to...
Positive safety profile in NORSE THREE open-label safety study reinforces previously reported safety data for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD Topline efficacy and safety data from pi...
MONMOUTH JUNCTION, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications...
MONMOUTH JUNCTION, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,...
Topline data from pivotal Phase 3 safety and efficacy study (NORSE TWO) on target to report in Q3 2021 Topline data from the open-label safety study (NORSE THREE) on target to report in Q2 2021 Recent funding significantly enhances financial position, extends cas...
MONMOUTH JUNCTION, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indicati...
Overallotment option on recent public offering partially exercised by underwriter Closed concurrent private placement for $3.0 million gross proceeds Aggregate gross proceeds of $41.6 million strengthens financial position and provides strategic optionality to maximize s...
MONMOUTH JUNCTION, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizum...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Series A Warrant Company Name:
OTLKW Stock Symbol:
NASDAQ Market:
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...
Live video webcast on Tuesday, June 18 th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; be...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...